Bibliography
- GORBACH SL, BARTLETT JG, BLACKLOW NR: InfectiousDiseases. WB Saunders, Philadelphia, USA (1992).
- WOLINSKY E: Mycobacterial diseases other than tuber-culosis. Clin. Infect. Dis. (1992) 15:1–12.
- SATHE SS, REICHMAN LB: Mycobacterial disease in pa-tients infected with the human immunodeficiency vi-rus. Clin. Chest Med. (1989) 10:445–463.
- CHOPRA I, BRENNAN P: Molecular action of anti-mycobacterial agents. Tubercule Lung Dis. (1998) 78. (In Press).
- ••Detailed, recent review on mechanisms of drug action
- ARMSTRONG D, NEU H, PETERSON LR, TOMASZ A: The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s. Microb. Drug Res. (1995) 1:1–4.
- ••Important reminder of the clinical consequences of antibi-otic resistance.
- DUNCAN K: Towards the next generation of drugs and vaccines for tuberculosis. Chem. Industry (1997) 3rd No-vember 861–865.
- •Useful overview of recent vaccine and drug opportunities.
- BELISLE JT, VISSA VD, SIEVERT T eta].: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 276:1420–1422.
- CLEMENS DL: Mycobacterium tuberculosis: bringing down the wall. Trends Microbiol. (1997) 5:383–385.
- SULING WJ, REYNOLDS RC, BARROW EW et al.: In vitro activity of lipophilic dihydrofolate reductase (DHFR) inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC). Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. Am. Soc. Microbiol. (1997) . Abstract F–42.
- CYNAMON M, LANG M, O'REILLY A, CHMIELEWSKI A, KLEMENS S: In vitro and in vivo activities of new nitro-imidazole derivatives against M tuberculosis (Mm). Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. Am. Soc. Mi-crobiol. (1997). Abstract F–30.
- TRIEBERG J A, CATS, TOWELL J A eta].: Synthesis and an-timycobacterial activity of novel nitroimidazopyrans. Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. Am. Soc. Mi-crobiol. (1997). Abstract F–24
- BARBACHYN MR, HUTCHINSON DK, BRICKNER SJ et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39:680–685.
- SLAYDEN RA, LEE RE, ARMOUR JW et al.: An ti-mycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. (1996) 40:2813–2819.